Studies Reveal That Most DTC Advertising Is for Drugs with Low Added Clinical Benefit

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

By signing up for a tour of the Thompson FDA Compliance Expert Suite, you are also registering to receive email offers and product updates from us. Simply click unsubscribe at the bottom of any email if you would like to discontinue delivery.

Studies Reveal That Most DTC Advertising Is for Drugs with Low Added Clinical Benefit

J.W. Schomisch

February 10, 2023 at 12:09 PM EST

A new study, published in JAMA Feb. 7, found that the share of promotional spending allocated to consumer advertising was on average 14.3 percentage points higher for drugs with low added benefit compared to drugs with high added benefit. “Allocating a greater share of promotional spending to consumer advertising (versus promotions that target clinicians) may therefore reflec... Read More

My Research Folders

You are not Logged in yet, Please login to see Your research folders.

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

Studies Reveal That Most DTC Advertising Is for Drugs with Low Added Clinical Benefit

My Research Folders

THOMPSON FDA

COMPLIANCE EXPERT

RESOURCES

HELP

CONTACT